Where does Aldeyra Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Aldeyra Therapeutics, Inc. ranks #8,156 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Aldeyra Therapeutics, Inc. hold?

Aldeyra Therapeutics, Inc. holds 39 US utility patents granted between 2016 and 2025, spanning 10 technology areas.

What is Aldeyra Therapeutics, Inc.'s Innovation Score?

Aldeyra Therapeutics, Inc. has an Innovation Score of 44.3 out of 100 (top 26% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Aldeyra Therapeutics, Inc. focus on?

Aldeyra Therapeutics, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 36 patents, ranking #522 of 6,058 assignees active in that subclass. Grants appear in 10 CPC subclasses total.

Is Aldeyra Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Aldeyra Therapeutics, Inc.'s recent grant velocity is +117% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Aldeyra Therapeutics, Inc.'s patents?

Aldeyra Therapeutics, Inc.'s patents average 19.5 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Aldeyra Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Aldeyra Therapeutics, Inc.

USPTO PatentsView assignee record - 39 granted patents across 10 technology areas, recorded in grant years 2016–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Aldeyra ranks #8,156 of 49,997 tracked US assignees by granted-patent volume, with 39 patents across 10 technology areas.

#8,156
of 49,997 US assignees by volume: Top 26%
by Innovation Score (44.3/100): 19.5
avg claims per patent: +117%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R8156 · US Corporation #8,156 · 39 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-SMALL 39 grants
UPPER-Q #8,156/49,997
PHOTO-FINISH Air Liquide…
CPC-FOCUS A61P · 10 areas
INNOV-PAR 44.3/100
CLAIMS-RICH 19.5 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +117% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Air Liquide Advanced Technologies U.S. LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Aldeyra’s 44.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 12.7 pts (29%) Velocity 8.7 pts (20%) Breadth 11.2 pts (25%) Claim depth 11.7 pts (26%)

Qualcomm Incorporated · highest

85
Catalina Marketing · near

44
Aldeyra Therapeutics · this assignee

44
kaleo · near

44
NTT · near

44
Sakata INX · near

44
3D Lighting… · lowest

7

What this shows Aldeyra's Innovation Score is 44.3/100 (top 26% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Aldeyra?

Each dot is one of Aldeyra’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Aldeyra’s own 19.5 claims/patent is ABOVE the 16.4 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Aldeyra vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Aldeyra's grants concentrate

Aldeyra Therapeutics, Inc. is a focused PatentsView assignee: 10 CPC subclasses with 92.3% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2024 (9 grants) versus a trough of 2 in 2016. By volume, Aldeyra sits between Atomic Energy OF Canada Limited and Arisaka LLC.

Aldeyra's three-year grant acceleration

Aldeyra Therapeutics, Inc. shows 17 grants in 2022–2024 against only 13 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Atomic Energy OF…

39
Aura Home

39
AYR

39
Air Liquide Advan…

39
American Science…

39
Apeel Technology

39
Apollo Tyres Glob…

39
Arisaka

39
Aldeyra Therapeut… ◀

39

What this shows Aldeyra holds 39 patents at rank #8,160, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Aldeyra

By rank, the assignees closest to #8,160 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Aldeyra's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Aldeyra, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Aldeyra ranks #522 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (44 here).

Sakata INX Corporation 44 kaleo, Inc. 44 NTT Electronics Corporation 44 Catalina Marketing Corporation 44

Aldeyra's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

44 Top 26% higher than 74% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Aldeyra Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	2	5.1%
2017	4	10.3%
2018	2	5.1%
2019	4	10.3%
2020	3	7.7%
2021	6	15.4%
2022	2	5.1%
2023	6	15.4%
2024	9	23.1%
2025partial year	1	2.6%

Which technologies does Aldeyra Therapeutics, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 36

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 35

C07D - Heterocyclic Compounds 19

C07C - Acyclic OR Carbocyclic Compounds 10

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 8

A61Q - Specific USE OF Cosmetics OR Similar Toiletry Preparations 8

C08K - Use of inorganic or non-macromolecular organic substances as compounding ingredients 8

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 1

C08B - POLYSACCHARIDES; Derivatives Thereof 1

C08L - Compositions OF Macromolecular Compounds 1

Top 10 of 10 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Aldeyra Therapeutics, Inc.'s patent record in context - here's where to go next.

Aldeyra Therapeutics, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 92.3% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #8,156 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Aldeyra Therapeutics, Inc. against Atomic Energy OF Canada Limited, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 44.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.